Candice Horbacz
The intricate framework of the United States tax code, particularly its treatment of research and development (R&D) expenditures, plays a pivotal role in shaping the strategic decisions of American companies regarding innovation and investment. This policy landscape dictates not only where R&D activities occur but also their scale and feasibility, directly influencing the nation’s economic competitiveness and technological leadership on a global stage. A recent divergence in this treatment, distinguishing between domestic and foreign R&D, has ignited a significant debate among economists, policymakers, and industry leaders about its implications for the future of American innovation.
The Evolving Landscape of R&D Tax Treatment: A Chronology of Policy Shifts
Historically, the US tax code provided a relatively consistent approach to R&D expenditures, often allowing for immediate deduction or "expensing" of these costs. This approach was widely seen as an incentive for companies to invest heavily in innovation, recognizing the long-term economic benefits that R&D brings. However, the early 2020s marked a critical turning point.
Prior to 2022, businesses could typically expense all R&D costs in the year they were incurred, a policy widely supported for its simplicity and pro-innovation stance. This changed dramatically with the enactment of the Tax Cuts and Jobs Act (TCJA) of 2017, which, while reducing corporate tax rates, included a provision (effective for tax years beginning after December 31, 2021) mandating the capitalization and amortization of all R&D expenses. Under this new regime, domestic R&D had to be amortized over five years (60 months), while foreign R&D faced an even longer amortization period of 15 years. This shift was met with widespread criticism from the business community and economic think tanks, including the Tax Foundation, who argued it would significantly deter R&D investment by increasing its effective cost. Industry associations, representing sectors heavily reliant on R&D such as technology, pharmaceuticals, and manufacturing, voiced strong opposition, warning of reduced innovation, job losses, and a decline in US global competitiveness.
In response to these concerns, particularly regarding domestic innovation, Congress reversed course for US-based R&D. The "One Big Beautiful Bill Act" (OBBBA), a colloquial reference to subsequent legislative action, reintroduced the option for taxpayers to immediately deduct domestic R&D under Section 174A. This provision allows companies to either expense domestic R&D immediately or amortize it over a period of at least 60 months, providing flexibility, especially for firms with net operating losses that might prefer to spread deductions over time. This legislative maneuver was largely driven by a desire to stimulate domestic innovation and investment, alongside considerations for budgetary impact.
However, a crucial omission in this reversal was the exclusion of foreign R&D. Under Section 174, foreign R&D expenditures continue to be subject to mandatory capitalization and amortization over 15 years, with no option for immediate expensing. This creates a stark divergence: a policy that actively encourages domestic innovation through immediate deductions, while simultaneously imposing a significantly longer, mandatory amortization schedule on R&D conducted abroad.
The motivations behind this differential treatment are understood to be twofold: first, to reduce the overall budgetary cost of the law, as immediate expensing represents a larger upfront tax deduction for the government; and second, to encourage the "onshoring" of R&D activities, aiming to bring innovation and associated economic benefits back to US soil. While these objectives might appear sound on the surface, their real-world implications for American multinational enterprises (MNEs) and the broader US economy warrant deeper scrutiny.
The Economic Mechanics: Expensing Versus Amortization
To fully grasp the impact of these tax policies, it’s essential to understand the fundamental economic distinction between expensing and amortization, particularly through the lens of the "time value of money." In economics, money available today is worth more than the same amount in the future due to its potential earning capacity. This principle critically influences investment decisions, as firms evaluate projects based on present and future revenues, expenses, and, crucially, tax payments.
A foundational analysis by economists Robert Hall and Dale Jorgenson in their 1967 research paper provided a framework for understanding how tax policy affects investment behavior through the "user cost of capital." The user cost of capital, represented by c, is essentially the hurdle rate – the minimum expected return – a project must clear to justify investment. Anything that increases c discourages investment at the margin, meaning projects that are just on the cusp of being worthwhile are more likely to be abandoned.
In the Hall-Jorgenson framework, a key variable, often denoted as z, captures the present value of the tax deductions a firm can claim on an investment, interacting with the corporate tax rate, τ. When z equals 1, signifying that the firm recovers the full value of its investment in tax deductions immediately (i.e., full expensing), the tax term in the cost-of-capital formula effectively cancels out. In this ideal scenario, the user cost of capital collapses to what it would be in the absence of any corporate tax, determined solely by the interest rate (r) and the depreciation rate (δ) of the investment. The effective marginal tax rate on a breakeven investment becomes zero. This is because the immediate tax benefit from expensing offsets the future tax burden on the income generated by a marginal project. The government, in essence, provides an upfront subsidy that neutralizes the disincentive of future taxation for new, marginal investments.
Conversely, amortization, particularly over extended periods like 15 years for foreign R&D, significantly alters this equation. By spreading deductions over many years, the present value of those deductions (z) falls below 1. This delay in tax relief means that the firm recovers less of its investment’s value in real terms, effectively increasing the user cost of capital above the no-tax baseline. Consequently, the hurdle rate for investment rises, and the tax code acts as a disincentive for new R&D projects, making some otherwise viable innovations financially unfeasible purely for tax reasons. Under the current US tax system, domestic R&D largely avoids this disincentive due to expensing, but foreign R&D faces a substantial penalty.
It is important to note that the "no tax" scenario for marginal investments under full expensing does not imply a tax system that raises no revenue. Inframarginal investments—those whose benefits significantly outweigh their costs—would still incur a positive tax burden. Similarly, pre-existing investments continue to generate taxable income and contribute to tax revenues irrespective of the depreciation schedule applied to new capital. The focus of the Hall-Jorgenson framework is on the marginal decision to undertake new investment.
The Debate: Complementarity, Not Substitution, in Global R&D
The policy rationale for excluding foreign R&D from immediate expensing often stems from a perception that domestic and international R&D are in direct competition. Lawmakers might believe that penalizing foreign R&D will encourage US companies to "onshore" these activities, thereby boosting domestic innovation and job creation. However, a substantial body of economic research and industry experience challenges this premise, arguing instead that international R&D is typically complementary to domestic activities, enhancing and scaling them rather than replacing them.
Economists Gary Hufbauer, Theodore Moran, and Lindsay Oldenski, in their extensive work on outbound foreign direct investment and its interaction with the US economy, have highlighted this complementarity. Their research, including a specific study on R&D, found that "global R&D expenditures and operations of US MNCs may create complementary capabilities and interdependent competencies, rather than simply displacing one capability or competency from location A to location B." This suggests that a US firm’s international R&D efforts often build upon, rather than detract from, its domestic innovation base.
Further commentary by Moran and Oldenski reinforced this view, stating that "measures to hinder or slow the globalization of R&D by US [multinational corporations] will stifle R&D by those multinationals in the United States." The Information Technology and Innovation Foundation (ITIF) has also presented findings that offshore research tends to complement domestic innovation. This occurs through several key mechanisms:
-
Market Adaptation: A significant function of foreign R&D is to adapt US-developed products and services for international markets. This includes modifying products for foreign languages, climates, infrastructure, payment systems, and cultural preferences. It also encompasses the crucial process of navigating and securing approval from diverse foreign regulatory systems, such as workplace safety standards, environmental regulations, or the rigorous clinical trials required for pharmaceuticals. Without this localized R&D, US companies would struggle to export their innovations globally, limiting their market reach and overall revenue potential, which in turn reduces resources for domestic R&D.
-
Acquisition of Global Talent and Ideas: Foreign R&D often involves the acquisition of international research teams, startups, or intellectual property (e.g., software patents, pharmaceutical compounds). A valuable idea or technology generated outside the US can be integrated into a large US company’s infrastructure, scaled globally, and further developed with additional investments back home. Penalizing foreign R&D could make such acquisitions less attractive or financially viable for US firms, hindering their ability to tap into the global pool of innovation.
-
Expansion of Knowledge Networks: Engaging in R&D abroad expands a firm’s global knowledge network, exposing it to new scientific discoveries, technological advancements, and diverse problem-solving approaches. This broader knowledge base can feed back into domestic R&D efforts, fostering cross-pollination of ideas and accelerating overall innovation.
In essence, penalizing foreign R&D is more likely to reduce a US company’s total cross-border knowledge production and innovation capacity than it is to produce meaningful gains at home. It risks creating a less integrated and less efficient global innovation ecosystem for US firms, ultimately weakening their competitive standing.
Impact on Global Competitiveness and Mergers & Acquisitions (M&A)
One direct and significant consequence of the disparate R&D tax treatment is its effect on the ability of US companies to compete in cross-border mergers and acquisitions (M&A), particularly for R&D-intensive targets. When a foreign acquisition target has substantial R&D operations or plans for future R&D spending, the tax treatment of those expenditures becomes a critical factor in its valuation.
Consider a scenario where a US company is bidding against a foreign competitor for an R&D-heavy foreign firm. If the US acquirer will be forced to amortize the target’s future R&D spending over 15 years, while the foreign competitor can expense it immediately under its home country’s tax laws, the US firm’s after-tax valuation of that target is structurally lower. This disadvantage can easily translate into losing bidding wars, denying US companies access to valuable intellectual property, talent, and market opportunities abroad.
The Semiconductor Industry Association (SIA) has explicitly articulated this concern, arguing that US chip firms face a tangible disadvantage when competing globally for innovative assets due to more favorable R&D tax treatment received by their foreign rivals. This insight, however, extends far beyond the semiconductor industry. The pharmaceutical sector, for instance, is highly M&A-driven, with large firms frequently acquiring smaller biotech companies or innovative drug pipelines. Similar dynamics apply to software, advanced materials, and various high-tech manufacturing industries, where R&D is a core asset.
The loss of these M&A transactions has multi-faceted negative consequences. Beyond the immediate financial implications for US firms, it can diminish the complementary benefits that such acquisitions often bring to the US economy, as discussed earlier. Furthermore, it could reduce the global reach and revenue-generation capacity of the US tax regime itself. If fewer businesses fall under the purview of US-resident companies due to competitive disadvantages, the broader tax base for the US government could shrink in the long run.
Industry Reactions and Calls for Policy Reform
The current tax disparity for R&D has not gone unnoticed by those directly affected. Industry leaders, particularly from multinational corporations across various sectors, have consistently voiced concerns. While not always in public "statements" directly inferable from the provided text, the arguments put forth by the Tax Foundation, PIIE, ITIF, and the Semiconductor Industry Association strongly reflect the perspectives of the business community. They highlight the competitive disadvantages, the disincentive to invest, and the broader economic harm.
Many industry representatives and economic policy experts advocate for a return to a neutral tax treatment of R&D expenditures, irrespective of where they occur. This would mean extending the option of immediate expensing to foreign R&D, aligning it with the treatment of domestic R&D. Such a move, they argue, would level the playing field for US-resident companies competing globally, encourage overall innovation by US MNEs, and enhance their ability to acquire and integrate valuable foreign research and development assets.
The debate underscores a fundamental tension between perceived short-term budgetary gains or nationalistic onshoring incentives and the long-term imperative of fostering a globally competitive and innovative US economy. Policymakers are urged to avoid creating artificial disadvantages that disproportionately burden foreign R&D performed by US multinational enterprises, as such policies ultimately risk stifling, rather than strengthening, American leadership in global innovation.
Broader Implications for US Innovation Leadership
In conclusion, the current bifurcated tax treatment of R&D within the US tax code presents a critical juncture for American innovation policy. While the intent to encourage domestic R&D and manage budgetary costs is understandable, the exclusion of foreign R&D from immediate expensing carries significant risks. It threatens to diminish the overall R&D investment by US companies, weaken their global competitiveness in critical sectors, and potentially disincentivize US tax residence for firms operating on an international scale.
A tax code that truly seeks to foster innovation and economic growth must recognize the integrated and complementary nature of global R&D. By moving towards a neutral tax treatment for all R&D expenditures, regardless of their geographic location, the United States can empower its multinational enterprises to expand their innovation activities, successfully compete for global talent and assets, and ultimately reinforce the nation’s position as a leader in the global knowledge economy. The ongoing legislative debate will determine whether policymakers prioritize a holistic view of US innovation or allow a segmented approach to impede the full potential of American enterprise on the world stage.
